From: Mark Harvey
Date: 06/02/2008 13:26:15
To: Jeremy Bryce
Subject: RE: ' Implementation of warnings on suicidal thoughts and behaviour in antidepressants' ..................source MHRA
Thank you for this.
The Seroxat Group Action does not involve suicide issues; only discontinuation where Seroxat is the worst of the comparator treatments."
We found some time ago that there was a Class Phenomenon for suicidal ideation and acts which meant that, together with other notable problems both in science and in law, successful litigation was unlikely. That was a decision I had to make irrespective of my personal concerns about these drugs and their links with suicidal ideation. It is noteworthy however that the original MHRA, EMEA and FDA investigations of SSRIs arose as a direct result of the focus on Seroxat and Paxil by the litigators both here and in the US and the media. That focus has highlighted the class issue.
I cannot, do not and will not talk for the various campaigners or support groups. Nor will I become involved in inter-campaigner disputes. As I have said on many occasions, every time the patients and their supporters snipe at each other it weakens their position and strengthens the Pharmaceutical Industry's.
Best wishes
Mark Harvey
Seroxat is also known as Paxil and Aropax. Blog exposes Bob Fiddaman Human rights abuser who won two SCIENTOLOGY CCHR (human rights!) awards.
blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1
This blog is brougt to you consistent with subsection 3 of the Protection from Harassment Act - i.e. blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1
Sunday, 31 October 2010
Journalists are not doctors. Indeed, some journalists feel they can play God with peoples' lives simply for a media frenzy
Journalists are not doctors. Indeed, some journalists feel they can play God with peoples' lives simply for a media frenzy. I say this from personal experience of many journalists including being questioned by Panorama at one point. A certain researcher once asked me to take a camera and film patients breaching their confidentiality. I refused. These people are not concerned with the welfare of patients but simply " a story". They also fail to be accountable for the vast range of problems they cause.
http://www.bmj.com/content/326/7402/1282.3.extract/reply
Kind Regards
Dr Rita Pal www.nhs-exposed.com
http://www.bmj.com/content/326/7402/1282.3.extract/reply
Kind Regards
Dr Rita Pal www.nhs-exposed.com
Panorama unscientific jumping on bandwagon & putting patients at risk - Dr Rita Pal
PANORAMA AND ADDED DRAMA
Rita Pal, Editor NHS Exposed http://www.nhs-exposed.com/
http://www.bmj.com/content/326/7402/1282.3.extract/reply
XXXXXXXXXXXXXXXXXX
Last year, I worked in the north. Panorama had just shown their supposedly well researched material on Paroxetine. Firstly, I think there seems to be an absence of clinical opinions on Paroxetine. I am therefore going to take this opportunity to present my opinion because I feel that clinical opinions from the person dealing with the side effects of the potent drug known as Panorama should be examined.
Many of my colleagues agree that Paroxetine has helped many people. Indeed, having
More...Last year, I worked in the north. Panorama had just shown their supposedly well researched material on Paroxetine. Firstly, I think there seems to be an absence of clinical opinions on Paroxetine. I am therefore going to take this opportunity to present my opinion because I feel that clinical opinions from the person dealing with the side effects of the potent drug known as Panorama should be examined.
Many of my colleagues agree that Paroxetine has helped many people. Indeed, having treated many people with the drug, there has been a significant improvement in their quality of life. Firstly, it should be borne in mind that Paroxetine is used to treat depressed people. This means the probability of suicidal ideation is much higher in this group of patients by the nature of their illness. Suicidal ideation is dependant on multiple factors eg environment, life events, mental state etc. No drug is perfect but this means a number of studies need to be done before the DOH issues guidelines based on a knee jerk reaction governed by Panorama.
After watching Panorama, a large amount of patients deteriorated as they simply "stopped their tablets" because of Panorama. This is an example where the media plays doctor. It is a known fact that abruptly stopping Paroxetine will give a number of withdrawal symptoms. Over that period of two weeks, we must have had about 40 patients suffering from relapses. These are people who had been well for a number of years on this drug.
Personally, having had the unfortunate experience of being in personal contact with Panorama in the past; I found them to be unscientific, jumping on whatever bandwagon they wish, featuring interviews from patients whose histories were not examined ie whether they were non compliant with medication or whether their suicide risk prior and after treatment had been examined. Fear instilled in vulnerable patients by a powerful medium like Panoram who have limited initial information on Paroxetine is dangerous.
The scientific data measuring the number of relapses following the Panorama programme is not publicised. Panorama should also take the responsibility of leaving doctors to pick up the pieces that they have created. They should also realise that they are playing with peoples' lives - which is not worth the terror journalism that was featured.
Currently we see a knee jerk reaction to a media frenzy.People who have recovered stop their medication and relapse badly. If Panorama want to pay for the extra admissions that they have directly caused, then they should provide me with their number. Indeed, perhaps they should sit up at 3am in the morning and take a look at what they have caused.
Journalists are not doctors. Indeed, some journalists feel they can play God with peoples' lives simply for a media frenzy. I say this from personal experience of many journalists including being questioned by Panorama at one point. A certain researcher once asked me to take a camera and film patients breaching their confidentiality. I refused. These people are not concerned with the welfare of patients but simply " a story". They also fail to be accountable for the vast range of problems they cause.
Kind Regards
Dr Rita Pal www.nhs-exposed.com
PS I would be interested to know whether Panorama would fund the beds we require for each relapsing patient with the first presenting line " Doctor, I stopped Paroxetine because Panorama featured all the bad points about it".
Competing interests: Interviewed by researcher from Panorama on a different subject.
Rita Pal, Editor NHS Exposed http://www.nhs-exposed.com/
http://www.bmj.com/content/326/7402/1282.3.extract/reply
XXXXXXXXXXXXXXXXXX
Last year, I worked in the north. Panorama had just shown their supposedly well researched material on Paroxetine. Firstly, I think there seems to be an absence of clinical opinions on Paroxetine. I am therefore going to take this opportunity to present my opinion because I feel that clinical opinions from the person dealing with the side effects of the potent drug known as Panorama should be examined.
Many of my colleagues agree that Paroxetine has helped many people. Indeed, having
More...Last year, I worked in the north. Panorama had just shown their supposedly well researched material on Paroxetine. Firstly, I think there seems to be an absence of clinical opinions on Paroxetine. I am therefore going to take this opportunity to present my opinion because I feel that clinical opinions from the person dealing with the side effects of the potent drug known as Panorama should be examined.
Many of my colleagues agree that Paroxetine has helped many people. Indeed, having treated many people with the drug, there has been a significant improvement in their quality of life. Firstly, it should be borne in mind that Paroxetine is used to treat depressed people. This means the probability of suicidal ideation is much higher in this group of patients by the nature of their illness. Suicidal ideation is dependant on multiple factors eg environment, life events, mental state etc. No drug is perfect but this means a number of studies need to be done before the DOH issues guidelines based on a knee jerk reaction governed by Panorama.
After watching Panorama, a large amount of patients deteriorated as they simply "stopped their tablets" because of Panorama. This is an example where the media plays doctor. It is a known fact that abruptly stopping Paroxetine will give a number of withdrawal symptoms. Over that period of two weeks, we must have had about 40 patients suffering from relapses. These are people who had been well for a number of years on this drug.
Personally, having had the unfortunate experience of being in personal contact with Panorama in the past; I found them to be unscientific, jumping on whatever bandwagon they wish, featuring interviews from patients whose histories were not examined ie whether they were non compliant with medication or whether their suicide risk prior and after treatment had been examined. Fear instilled in vulnerable patients by a powerful medium like Panoram who have limited initial information on Paroxetine is dangerous.
The scientific data measuring the number of relapses following the Panorama programme is not publicised. Panorama should also take the responsibility of leaving doctors to pick up the pieces that they have created. They should also realise that they are playing with peoples' lives - which is not worth the terror journalism that was featured.
Currently we see a knee jerk reaction to a media frenzy.People who have recovered stop their medication and relapse badly. If Panorama want to pay for the extra admissions that they have directly caused, then they should provide me with their number. Indeed, perhaps they should sit up at 3am in the morning and take a look at what they have caused.
Journalists are not doctors. Indeed, some journalists feel they can play God with peoples' lives simply for a media frenzy. I say this from personal experience of many journalists including being questioned by Panorama at one point. A certain researcher once asked me to take a camera and film patients breaching their confidentiality. I refused. These people are not concerned with the welfare of patients but simply " a story". They also fail to be accountable for the vast range of problems they cause.
Kind Regards
Dr Rita Pal www.nhs-exposed.com
PS I would be interested to know whether Panorama would fund the beds we require for each relapsing patient with the first presenting line " Doctor, I stopped Paroxetine because Panorama featured all the bad points about it".
Competing interests: Interviewed by researcher from Panorama on a different subject.
SSRI suicide linked Citalopram now UK largest seller - x5+ times greater than seroxat
ST. LOUIS A month after its Earth City subsidiary pleaded guilty of illegally marketing antidepressants to children and adolescents, Forest Laboratories is now settling a string of wrongful death and personal injury lawsuits from the parents of children who took the drugs Celexa and Lexapro.
Fifty-four lawsuits, mostly involving suicides and attempted suicides by teenagers in various parts of the country, accuse the New York-based pharmaceutical company of concealing a negative pediatric study on Celexa, duping physicians about the drug's clinical trials, and targeting children in aggressive promotions of Celexa and a sister drug, Lexapro.
Four of the cases were settled Friday, and two additional cases were settled in recent weeks.
A surge of related settlements, which could total millions of dollars, is expected in the months ahead as the pharmaceutical company attempts to move beyond the controversy surrounding its marketing of antidepressants to children.
http://www.stltoday.com/business/article_c569f2c4-58a7-5432-a939-ff22e90583e5.html
2009 UK Citalopram prescriptions = 10.5 million
UK Escitalopram prescriptions = 1.25 million
i.e together very nearly 50% of the UK market !
Tuesday1st The UK Seroxat Litigation Chronicles
http://the-uk-seroxat-litigation-chronicles.blogspot.com/
Tuesday1st UK : SSRI / SNRI Antidepressant Statistical Politics
http://tuesday1st.blogspot.com/
Tuesday1st Correspondence with the MHRA .. Patient & Public Engagement Strategy
http://tuesday1st-mhra-ppes-correspondence.blogspot.com/
Celexa (cipramil) Lexapro settling suits over drugs tied to suicides
http://www.stltoday.com/business/article_c569f2c4-58a7-5432-a939-ff22e90583e5.html
ST. LOUIS A month after its Earth City subsidiary pleaded guilty of illegally marketing antidepressants to children and adolescents, Forest Laboratories is now settling a string of wrongful death and personal injury lawsuits from the parents of children who took the drugs Celexa and Lexapro.
Fifty-four lawsuits, mostly involving suicides and attempted suicides by teenagers in various parts of the country, accuse the New York-based pharmaceutical company of concealing a negative pediatric study on Celexa, duping physicians about the drug's clinical trials, and targeting children in aggressive promotions of Celexa and a sister drug, Lexapro.
Four of the cases were settled Friday, and two additional cases were settled in recent weeks.
A surge of related settlements, which could total millions of dollars, is expected in the months ahead as the pharmaceutical company attempts to move beyond the controversy surrounding its marketing of antidepressants to children.
Last month, the company's subsidiary Forest Pharmaceuticals, based in Earth City agreed to plead guilty to criminal charges involving its marketing and manufacturing practices and also to pay more than $300 million in criminal and civil penalties. The U.S. attorney's office in Boston is continuing to investigate the potential criminal liability of Forest officers and employees.
According to federal regulators, Forest waged an aggressive campaign from 1999 through at least 2005 to promote the use of Celexa and Lexapro in children and teenagers, although neither drug was approved for pediatric use.
Details of Forest Laboratories' monetary settlements with aggrieved families have not been made public, but the lawsuits themselves present a glimpse of the alleged harm caused by the company, including hefty payments to pediatricians and other physicians to tout the benefits of the drugs.
In vivid detail, the complaints allege that children under the influence of Celexa and Lexapro committed acts of suicide and violence. And the victims' families accuse the pharmaceutical company of fraud and negligence in failing to warn physicians and the public about the drugs' known dangers.
But the settlements are cloaked in secrecy, with each side vowing not to disclose the dollar amounts paid or other aspects of their agreements.
Frank Murdolo, the chief spokesman for Forest Laboratories, was unavailable for comment.
Harris Pogust, a Pennsylvania attorney who is the plaintiffs' lead counsel in the multidistrict litigation, said, "I can't really discuss anything that's going on between the parties."
The Celexa and Lexapro cases have been consolidated in federal court in St. Louis.
Several years ago, some of Pogust's clients testified before Congress and the Food and Drug Administration about the dangers of marketing the drugs to children.
One of the cases settled Friday involves Andrew Tradd of Massachusetts, who was 13 when he tried to hang himself in April 2004. Seven days later, he died as a result of a brain injury suffered in that attempted suicide. He had been prescribed Celexa in 2002.
According to his family's lawsuit, Forest was aware through numerous studies that some patients taking Celexa and similar drugs were much more at risk of suicidal behavior but chose not to warn physicians or strengthen the warning on the drug's packaging.
Celexa's sales skyrocketed from $92 million in 1999 to $1.6 billion in 2002. But the firm was under pressure to sell as much of Celexa as possible because the U.S. patent on the drug would expire in 2004.
H. Lundbeck, a Danish firm that developed Celexa, had placed a suicide warning on the drug in Europe for many years but not in the United States until a "black box" warning was mandated for Celexa and similar drugs in 2004 by the FDA.
The Tradd lawsuit and another suit quote Howard Solomon, the chairman and chief executive of Forest Laboratories, as saying in a letter to shareholders, "We believe that the studies and experience with our products, Lexapro and Celexa, do not indicate any increased suicidality."
But the Tradd family alleged that "contrary to these claims, for years Forest Laboratories Inc., was aware of clinical trials that showed that some persons who took Celexa suffered damaging side affects including agitation, aggressive and suicidal tendencies."
Another settled case involves Rachel Weiss of Belchertown, Mass., who was 16 in November 2002 when she suffered a panic attack while at school. En route to the school nurse's office, her suit alleges, Rachel threw herself down concrete and metal stairs, causing permanent injuries to her back and spine.
A high school sophomore, she had been taking Celexa for about nine days for depression and anxiety. After she began taking Celexa, the suit alleges, "her symptoms worsened dramatically."
In 2002, a four-year clinical trial by the Danish Lundbeck firm revealed that Celexa did not help depressed adolescents more than a placebo. But the results were not made public until 2004, when they appeared on a single line of a chart contained in a Danish textbook, the suit alleges.
The U.S. attorney's office in Boston has asserted that the results of the Lundbeck trial had been provided to Forest two years earlier, but the company chose to keep the negative results hidden from the public.
Another settled case involved Danielle Henrikson, who was 15 when she hanged herself in the garage of her parents' Idaho home in July 2004. Within a few weeks after taking Celexa, their lawsuit alleges, her condition began to deteriorate.
"The company suppressed the negative results of some studies, which showed that Celexa could cause an increased risk of suicidal thinking and acts in those adolescents who were prescribed to it," the suit alleges.
Forest Laboratories denied the allegation in court documents.
A case settled Friday was on behalf of Alex Kim of Gwinnett County, Ga., who hanged himself in June 2004 when he was 13 after his Lexapro dosage had been doubled. He had been taking the drug for about three months.
In their lawsuit, Alex's parents asked for $10 million in general damages, plus $10 million in punitive damages from Forest for "failing to provide information regarding serious health risks, failing to publicize the risks, failing to timely alert the public, and failing to recall the product."
Even if settlements over Celexa and Lexapro end up costing Forest Laboratories tens of millions of dollars, Wall Street experts don't expect the outlays to significantly impact the company's profit margins.
"I don't think that's really going to affect the stock price," said Annabel Samimy, an analyst at Stifel Nicholas & Co. Inc. "People don't really focus on Lexapro as being the long-term future of the company. Any settlement of wrongful death suits can be absorbed by the company, especially given the $4 billion in cash they're sitting on."
ST. LOUIS A month after its Earth City subsidiary pleaded guilty of illegally marketing antidepressants to children and adolescents, Forest Laboratories is now settling a string of wrongful death and personal injury lawsuits from the parents of children who took the drugs Celexa and Lexapro.
Fifty-four lawsuits, mostly involving suicides and attempted suicides by teenagers in various parts of the country, accuse the New York-based pharmaceutical company of concealing a negative pediatric study on Celexa, duping physicians about the drug's clinical trials, and targeting children in aggressive promotions of Celexa and a sister drug, Lexapro.
Four of the cases were settled Friday, and two additional cases were settled in recent weeks.
A surge of related settlements, which could total millions of dollars, is expected in the months ahead as the pharmaceutical company attempts to move beyond the controversy surrounding its marketing of antidepressants to children.
Last month, the company's subsidiary Forest Pharmaceuticals, based in Earth City agreed to plead guilty to criminal charges involving its marketing and manufacturing practices and also to pay more than $300 million in criminal and civil penalties. The U.S. attorney's office in Boston is continuing to investigate the potential criminal liability of Forest officers and employees.
According to federal regulators, Forest waged an aggressive campaign from 1999 through at least 2005 to promote the use of Celexa and Lexapro in children and teenagers, although neither drug was approved for pediatric use.
Details of Forest Laboratories' monetary settlements with aggrieved families have not been made public, but the lawsuits themselves present a glimpse of the alleged harm caused by the company, including hefty payments to pediatricians and other physicians to tout the benefits of the drugs.
In vivid detail, the complaints allege that children under the influence of Celexa and Lexapro committed acts of suicide and violence. And the victims' families accuse the pharmaceutical company of fraud and negligence in failing to warn physicians and the public about the drugs' known dangers.
But the settlements are cloaked in secrecy, with each side vowing not to disclose the dollar amounts paid or other aspects of their agreements.
Frank Murdolo, the chief spokesman for Forest Laboratories, was unavailable for comment.
Harris Pogust, a Pennsylvania attorney who is the plaintiffs' lead counsel in the multidistrict litigation, said, "I can't really discuss anything that's going on between the parties."
The Celexa and Lexapro cases have been consolidated in federal court in St. Louis.
Several years ago, some of Pogust's clients testified before Congress and the Food and Drug Administration about the dangers of marketing the drugs to children.
One of the cases settled Friday involves Andrew Tradd of Massachusetts, who was 13 when he tried to hang himself in April 2004. Seven days later, he died as a result of a brain injury suffered in that attempted suicide. He had been prescribed Celexa in 2002.
According to his family's lawsuit, Forest was aware through numerous studies that some patients taking Celexa and similar drugs were much more at risk of suicidal behavior but chose not to warn physicians or strengthen the warning on the drug's packaging.
Celexa's sales skyrocketed from $92 million in 1999 to $1.6 billion in 2002. But the firm was under pressure to sell as much of Celexa as possible because the U.S. patent on the drug would expire in 2004.
H. Lundbeck, a Danish firm that developed Celexa, had placed a suicide warning on the drug in Europe for many years but not in the United States until a "black box" warning was mandated for Celexa and similar drugs in 2004 by the FDA.
The Tradd lawsuit and another suit quote Howard Solomon, the chairman and chief executive of Forest Laboratories, as saying in a letter to shareholders, "We believe that the studies and experience with our products, Lexapro and Celexa, do not indicate any increased suicidality."
But the Tradd family alleged that "contrary to these claims, for years Forest Laboratories Inc., was aware of clinical trials that showed that some persons who took Celexa suffered damaging side affects including agitation, aggressive and suicidal tendencies."
Another settled case involves Rachel Weiss of Belchertown, Mass., who was 16 in November 2002 when she suffered a panic attack while at school. En route to the school nurse's office, her suit alleges, Rachel threw herself down concrete and metal stairs, causing permanent injuries to her back and spine.
A high school sophomore, she had been taking Celexa for about nine days for depression and anxiety. After she began taking Celexa, the suit alleges, "her symptoms worsened dramatically."
In 2002, a four-year clinical trial by the Danish Lundbeck firm revealed that Celexa did not help depressed adolescents more than a placebo. But the results were not made public until 2004, when they appeared on a single line of a chart contained in a Danish textbook, the suit alleges.
The U.S. attorney's office in Boston has asserted that the results of the Lundbeck trial had been provided to Forest two years earlier, but the company chose to keep the negative results hidden from the public.
Another settled case involved Danielle Henrikson, who was 15 when she hanged herself in the garage of her parents' Idaho home in July 2004. Within a few weeks after taking Celexa, their lawsuit alleges, her condition began to deteriorate.
"The company suppressed the negative results of some studies, which showed that Celexa could cause an increased risk of suicidal thinking and acts in those adolescents who were prescribed to it," the suit alleges.
Forest Laboratories denied the allegation in court documents.
A case settled Friday was on behalf of Alex Kim of Gwinnett County, Ga., who hanged himself in June 2004 when he was 13 after his Lexapro dosage had been doubled. He had been taking the drug for about three months.
In their lawsuit, Alex's parents asked for $10 million in general damages, plus $10 million in punitive damages from Forest for "failing to provide information regarding serious health risks, failing to publicize the risks, failing to timely alert the public, and failing to recall the product."
Even if settlements over Celexa and Lexapro end up costing Forest Laboratories tens of millions of dollars, Wall Street experts don't expect the outlays to significantly impact the company's profit margins.
"I don't think that's really going to affect the stock price," said Annabel Samimy, an analyst at Stifel Nicholas & Co. Inc. "People don't really focus on Lexapro as being the long-term future of the company. Any settlement of wrongful death suits can be absorbed by the company, especially given the $4 billion in cash they're sitting on."
"The simple story is that GSK were running a factory in Puerto Rico - so too was Schering-Plough
just don't expect Bob Fiddam to tell the whole story !
http://bobfiddaman.blogspot.com/2010/10/puerto-rico-defective-drugs-not-unique.html
In May 2002, Schering-Plough agreed to pay a record $500m (€390m) fine after signing a decree to improve manufacturing standards at its facilities in Puerto Rico and New Jersey used for the production of its antihistamine Claritin (loratadine).
http://bobfiddaman.blogspot.com/2010/10/puerto-rico-defective-drugs-not-unique.html
Saturday, 30 October 2010
Puerto Rico Defective drugs NOT unique to Glaxo - In May 2002, Schering-Plough agreed to pay a record $500m (€390m) fine
In May 2002, Schering-Plough agreed to pay a record $500m (€390m) fine after signing a decree to improve manufacturing standards at its facilities in Puerto Rico and New Jersey used for the production of its antihistamine Claritin (loratadine).
source
http://www.in-pharmatechnologist.com/Processing-QC/GSK-signs-consent-decree-for-Cidra-plant
GlaxoSmithKline has signed a consent decree with the US Food and Drug Administration to correct manufacturing deficiencies at its Cidra, Puerto Rico facility, but could be in a position to return two drugs made at the plant to market within the next few weeks, reports Phil Taylor.
In March, the FDA and the US Department of Justice seized batches of GSK's diabetes treatment Avandamet (rosiglitazone plus metformin), and its antidepressant, Paxil CR (paroxetine), saying they failed to meet quality standards. The interruption in supply has already cost GSK around €300m in lost sales.
The signing of a consent decree means that a company commits to putting problems right, but also lays it open to the risk of fines and complete closure of the offending plant if matters cannot be rectified. In May 2002, Schering-Plough agreed to pay a record $500m (€390m) fine after signing a decree to improve manufacturing standards at its facilities in Puerto Rico and New Jersey used for the production of its antihistamine Claritin (loratadine).
In this case, the liability for GSK is around $10m a year if it fails to meet the terms of the decree, but analysts said this was lower than some had expected, and crucially did not include any penalties for the perod leading up to the discovery of the problem. A number of managerial staff have been fired in the wake of the probe.
The FDA said after news of the consent decree came out that it was concerned that "GSK's violation of manufacturing standards may have resulted in the production of drug products that could potentially pose risks to consumers."
The decree also requires GSK to post a penal bond of $650m to ensure thatproduct previously withheld by the FDA is appropriately destroyed or reconditioned.
Under the terms of this decree, the company has agreed to take measures to ensure that the Cidra facility fully complies with current Good Manufacturing Practice ( cGMP) requirements and to ensure that ongoing shipments have the quality attributes they are required to possess. The decree also requires that all corrections and the firm's compliance with cGMP requirements be certified by a third-party expert.
"The consent decree shows that FDA is serious about enforcing the manufacturing standards essential for safe and effective prescription drugs," said John Taylor, FDA Associate Commissioner for Regulatory Affairs.
The FDA's last inspection of the Cidra found Paxil CR tablets, approved to treat depression and panic disorder, could split apart. This deficiency could cause patients to receive a portion of the tablets that lacks any active ingredient, or alternatively a portion that contains an active ingredient and does not have the intended controlled-release effect. Additionally, FDA found that some Avandamet tablets did not have an accurate dose of rosiglitazone.
SkyePharma compensated
Meanwhile, UK company SkyePharma, which supplied the drug delivery technology underlying Paxil CR, will be paid a lump sum of around $10m to compensate for the loss of royalty revenues resulting from the withdrawal of the drug.
In addition, SkyePharma will also be entitled to an increase in the royalty rate from 3 to 4 per cent on actual net sales of Paxil CR, with effect from March 4, 2005, in settlement of a dispute between the two companies.
GLAXO VIOLATIONS Cidra Puerto Rico - Cheryl D. Eckard - GSK Puerto Rico - Qui tam
http://f1.grp.yahoofs.com/v1/YLTLTONyftFdAUyhBWiaC1zWJYJmHgVUodPVYqQXU45NQnQZoMOZ8RgYilHDEedy4f_8f2vxnv6pxxoDcHsP/GLAXO%20VIOLATIONS%20Cidra%20Puerto%20Rico.pdf
GLAXO VIOLATIONS Cidra Puerto Rico.pdf
Cheryl D. Eckard - GSK Puerto Rico - Qui tam
GLAXO VIOLATIONS Cidra Puerto Rico.pdf
Cheryl D. Eckard - GSK Puerto Rico - Qui tam
Paxil Puerto Rico "split pill" total damages $28million @ max$150 per person
Settlement Proposed in Paxil Class Action Lawsuit
Date Published: Friday, March 27th, 2009
http://www.newsinferno.com/pharmaceuticals/settlement-proposed-in-paxil-class-action-lawsuit/
A settlement has been proposed in the so-called Paxil “split pill” class action lawsuit. According to a press release, if approved, the settlement will provide up to $28 million to claimants and their insurance companies.
Paxil is part of a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs). Paxil was approved to treat symptoms of depression, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), panic disorder, generalized anxiety disorder (GAD), social phobia/social anxiety disorder, and premenstrual dysphoric disorder (PMDD). Paxil was the first antidepressant formally approved in the US for the treatment of social anxiety disorder.
The drug has been linked to a variety of problems, including birth defects, as well as suicide and suicidal tendencies when taken by young people and children. Yet in spite of these risks, by 2006 Paxil was the fifth most-commonly prescribed antidepressant in the US, with more than 19.7 million prescriptions.
The Paxil “spit pill” class action lawsuit alleges that Paxil “controlled release” (CR) tablets made between April 1, 2002 and March 4, 2005, contained a manufacturing defect that caused them to split apart. According to the complaint, Paxil CR tablets are intended to deliver the active ingredient over a period of time, and not all at once. When one splits apart, the outside coat breaks up and the drug is released while the tablets are still in the stomach. Patients end up with all of the active ingredient, without the benefits of the controlled-release, and received the entire dose at once. Or they get only the controlled-release ingredient without the active ingredients, the complaint says.
In March 2005, armed marshals with the Food and Drug Administration The Sandlot release (FDA) raided GlaxoSmithKline plants in Puerto Rico and Tennessee after learning that some pills manufactured there had split apart. The FDA had originally discovered the problem at the Puerto Rico plant in February 2002, and the problem continued despite repeated warnings and inspections, the complaint charges.
If approved, the $28 million settlement will be split between consumers who paid for their Paxil and insurance companies seeking to be reimbursed for their expenditures. The amount each class member recovers will depend on how many defective pills they bought, with a maximum recovery of $150 per person. A final approval hearing will be held on July 10, 2009.
Under the settlement, GlaxoSmithKline denies liability and all of the claims in the lawsuit.
NewsInferno.com disclaimer: This article: Settlement Proposed in Paxil Class Action Lawsuit was posted on Friday, March 27th, 2009 at 8:52 am at NewsInferno.com and is filed under Pharmaceuticals.
Date Published: Friday, March 27th, 2009
http://www.newsinferno.com/pharmaceuticals/settlement-proposed-in-paxil-class-action-lawsuit/
A settlement has been proposed in the so-called Paxil “split pill” class action lawsuit. According to a press release, if approved, the settlement will provide up to $28 million to claimants and their insurance companies.
Paxil is part of a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs). Paxil was approved to treat symptoms of depression, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), panic disorder, generalized anxiety disorder (GAD), social phobia/social anxiety disorder, and premenstrual dysphoric disorder (PMDD). Paxil was the first antidepressant formally approved in the US for the treatment of social anxiety disorder.
The drug has been linked to a variety of problems, including birth defects, as well as suicide and suicidal tendencies when taken by young people and children. Yet in spite of these risks, by 2006 Paxil was the fifth most-commonly prescribed antidepressant in the US, with more than 19.7 million prescriptions.
The Paxil “spit pill” class action lawsuit alleges that Paxil “controlled release” (CR) tablets made between April 1, 2002 and March 4, 2005, contained a manufacturing defect that caused them to split apart. According to the complaint, Paxil CR tablets are intended to deliver the active ingredient over a period of time, and not all at once. When one splits apart, the outside coat breaks up and the drug is released while the tablets are still in the stomach. Patients end up with all of the active ingredient, without the benefits of the controlled-release, and received the entire dose at once. Or they get only the controlled-release ingredient without the active ingredients, the complaint says.
In March 2005, armed marshals with the Food and Drug Administration The Sandlot release (FDA) raided GlaxoSmithKline plants in Puerto Rico and Tennessee after learning that some pills manufactured there had split apart. The FDA had originally discovered the problem at the Puerto Rico plant in February 2002, and the problem continued despite repeated warnings and inspections, the complaint charges.
If approved, the $28 million settlement will be split between consumers who paid for their Paxil and insurance companies seeking to be reimbursed for their expenditures. The amount each class member recovers will depend on how many defective pills they bought, with a maximum recovery of $150 per person. A final approval hearing will be held on July 10, 2009.
Under the settlement, GlaxoSmithKline denies liability and all of the claims in the lawsuit.
NewsInferno.com disclaimer: This article: Settlement Proposed in Paxil Class Action Lawsuit was posted on Friday, March 27th, 2009 at 8:52 am at NewsInferno.com and is filed under Pharmaceuticals.
Friday, 29 October 2010
The effect of publication on Internet-based solicitation of personal-injury litigants
Abstract
Serious adverse drug events can prompt personal-injury lawsuits. However, the extent to which biomedical publication regarding drug-induced harm can influence the legal process has not been well characterized. Using an advanced Google search strategy, we determined the number of Internet "hits" for websites soliciting plaintiffs for medicolegal action before and after publication of a study that highlighted the risk of dysglycemia among patients taking the antibiotic gatifloxacin. We found that early online release and print publication were associated with an immediate and sustained increase in the number of websites soliciting plaintiffs for legal action.
Figure 1: Average number of medicolegal Internet hits before and after publication of an article in the New England Journal of Medicine about the adverse events associated with gatifloxacin.
From:CMAJ. 2007 November 20; 177(11): 1369–1370.
doi: 10.1503/cmaj.070652.Copyright © 2007 Canadian Medical Association or its licensors
http://www.ncbi.nlm.nih.gov/pubmed/18025428
Serious adverse drug events can prompt personal-injury lawsuits. However, the extent to which biomedical publication regarding drug-induced harm can influence the legal process has not been well characterized. Using an advanced Google search strategy, we determined the number of Internet "hits" for websites soliciting plaintiffs for medicolegal action before and after publication of a study that highlighted the risk of dysglycemia among patients taking the antibiotic gatifloxacin. We found that early online release and print publication were associated with an immediate and sustained increase in the number of websites soliciting plaintiffs for legal action.
Figure 1: Average number of medicolegal Internet hits before and after publication of an article in the New England Journal of Medicine about the adverse events associated with gatifloxacin.
From:CMAJ. 2007 November 20; 177(11): 1369–1370.
doi: 10.1503/cmaj.070652.Copyright © 2007 Canadian Medical Association or its licensors
http://www.ncbi.nlm.nih.gov/pubmed/18025428
Antidepressant discontinuation (withdrawal) symptoms were first reported 1959 - 5 years before Fiddaman's birth
Antidepressant discontinuation (withdrawal) symptoms were first reported in association with imipramine (Mann & MacPherson, 1959; Andersen & Kristiansen, 1959), the first tricyclic antidepressant (TCA), shortly after it entered clinical use. These symptoms occur with all classes of antidepressant, including the TCAs, monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin and noradrenaline reuptake inhibitors (SNRIs) and miscellaneous others such as mirtazapine, a noradrenergic and specific serotonergic antidepressant (NaSSA). A PubMed review conducted when preparing this article identified reports of discontinuation symptoms with 25 antidepressants (Box 1
). In recent years the phenomenon has attracted increasing interest, in both the scientific literature and in the lay media (BBC Panorama, 2002, 2003). This article provides an overview of the clinical features of antidepressant discontinuation symptoms, with the emphasis on their recognition, prevention and management. Discontinuation symptoms can occur whenever antidepressants are used, i.e. they are not dependent on the presence of any underlying psychiatric disorder. The pharmacokinetics and dynamics of antidepressants, in particular their half-life, are important determinants of discontinuation symptoms, as are individual patient characteristics, but their discussion is beyond the scope of this article (Schatzberg et al, 1997; Haddad, 1998; Bogetto et al, 2002).
http://apt.rcpsych.org/cgi/content/full/13/6/447
Can Psychiatr Assoc J. 1959 Jan;4(1):38-47.
Clinical experience with imipramine (G22355) in the treatment of depression.
MANN AM, MACPHERSON AS.
PMID: 13629473 [PubMed - indexed for MEDLINE]
MeSH Terms, SubstancesMeSH Terms:Depression/therapy*Tranquilizing Agents/therapeutic use*Substances:Tranquilizing Agents
LinkOut - more resources
http://apt.rcpsych.org/cgi/content/full/13/6/447
Can Psychiatr Assoc J. 1959 Jan;4(1):38-47.
Clinical experience with imipramine (G22355) in the treatment of depression.
MANN AM, MACPHERSON AS.
PMID: 13629473 [PubMed - indexed for MEDLINE]
MeSH Terms, SubstancesMeSH Terms:Depression/therapy*Tranquilizing Agents/therapeutic use*Substances:Tranquilizing Agents
LinkOut - more resources
Thursday, 28 October 2010
Antidepressants reported to cause discontinuation symptoms - NOT JUST SEROXAT !
Antidepressants reported to cause discontinuation symptoms
http://apt.rcpsych.org/cgi/content/full/13/6/447
Tricyclic and related compounds
Amineptine
Amitriptyline
Amoxapine
Clomipramine
Desipramine
Doxepin
Imipramine
Nortriptyline
Protriptyline
Trazodone
Monoamine oxidase inhibitors
Isocarboxazid
Moclobemide
Phenelzine
Tranylcypromine
Selective serotonin reuptake inhibitors
Citalopram
Escitalopram
Fluoxetine
Fluvoxamine
Paroxetine
Sertraline
Serotonin and noradrenaline reuptake inhibitors
Duloxetine
Milnacipran
Venlafaxine
Miscellaneous antidepressants
Mirtazapine (noradrenergic and specific serotonergic antidepressant, NaSSA)
Nefazodone
(Based on the authors’ literature review)
http://apt.rcpsych.org/cgi/content/full/13/6/447
Tricyclic and related compounds
Amineptine
Amitriptyline
Amoxapine
Clomipramine
Desipramine
Doxepin
Imipramine
Nortriptyline
Protriptyline
Trazodone
Monoamine oxidase inhibitors
Isocarboxazid
Moclobemide
Phenelzine
Tranylcypromine
Selective serotonin reuptake inhibitors
Citalopram
Escitalopram
Fluoxetine
Fluvoxamine
Paroxetine
Sertraline
Serotonin and noradrenaline reuptake inhibitors
Duloxetine
Milnacipran
Venlafaxine
Miscellaneous antidepressants
Mirtazapine (noradrenergic and specific serotonergic antidepressant, NaSSA)
Nefazodone
(Based on the authors’ literature review)
Recognising and managing antidepressant discontinuation symptoms
Recognising and managing antidepressant discontinuation symptoms
http://apt.rcpsych.org/cgi/content/full/13/6/447
http://apt.rcpsych.org/cgi/content/full/13/6/447
SSRI withdrawal protocols from APRIL - founded 1998 by Millie Kieve
In 1998, I founded the charity April (Adverse Psychiatric Reactions Information Link), which was also the month of Karen's birthday. I hoped that, by increasing awareness, perhaps the terrible waste of her life could save someone else's.
I now receive a constant flow of emails reporting the same kind of experiences as Karen's. People tell me how helpful they find it that someone understands. One woman who was very depressed, showed her doctor medical information that I had sent her. Only then did he agree to change the medication for her heart problems."I feel 600% better," she told me.
I send out withdrawal protocols to help doctors support their patients during withdrawal from SSRI antidepressants and benzodiazepines, as well as presenting workshops for health professionals to persuade them to report ADRs on Yellow Cards, the side-effect reporting system which, 40 years after its conception, is still not effective. I also contribute evidence to department of health and government inquiries and organise conferences. The next one, Adverse Psychiatric Reactions to Medicines and Anaesthetics, is on November 4.
April is now the main focus of my life and I campaign on all sorts of issues, from demanding that coroners record all drugs prescribed, stopped or doses changed, in the months prior to sudden death, to making sure that medical students understand about ADRs. I can never bring my lovely daughter back but it is a comfort to be able to help others. I believe awareness saves lives and have taken on the task of bringing that awareness to the medical profession and the public.
· www.april.org.uk
http://www.guardian.co.uk/society/2004/aug/17/health.lifeandhealth
I now receive a constant flow of emails reporting the same kind of experiences as Karen's. People tell me how helpful they find it that someone understands. One woman who was very depressed, showed her doctor medical information that I had sent her. Only then did he agree to change the medication for her heart problems."I feel 600% better," she told me.
I send out withdrawal protocols to help doctors support their patients during withdrawal from SSRI antidepressants and benzodiazepines, as well as presenting workshops for health professionals to persuade them to report ADRs on Yellow Cards, the side-effect reporting system which, 40 years after its conception, is still not effective. I also contribute evidence to department of health and government inquiries and organise conferences. The next one, Adverse Psychiatric Reactions to Medicines and Anaesthetics, is on November 4.
April is now the main focus of my life and I campaign on all sorts of issues, from demanding that coroners record all drugs prescribed, stopped or doses changed, in the months prior to sudden death, to making sure that medical students understand about ADRs. I can never bring my lovely daughter back but it is a comfort to be able to help others. I believe awareness saves lives and have taken on the task of bringing that awareness to the medical profession and the public.
· www.april.org.uk
http://www.guardian.co.uk/society/2004/aug/17/health.lifeandhealth
Hugh James solicitors Mark Harvey a seroxat patient ? - how very disturbing
The Evidence, However is Clear
http://health.groups.yahoo.com/group/seroxat/
Description
"A group to discuss the side effects, withdrawal symptoms and associated addiction to the anti-depressant Seroxat.
Take a look at the websites in the links section for detailed info on safe withdrawal and tapering, professional contacts, media articles and the latest research. "
CCHR - I want to be a Commissioner for CCHR says Bob Fiddaman - The Evidence is Clear
Am I a Commissioner for CCHR? No, but I sure would like to be. They are at the forefront of raising awareness about this fraudulent industry and if that means someone labelling me a Scientologist then that is a very small price to pay for someone else's ignorance
http://bobfiddaman.blogspot.com/2010/10/fiddaman-is-cchr-shill-read-his-words.html
http://bobfiddaman.blogspot.com/2010/10/fiddaman-is-cchr-shill-read-his-words.html
367 community treatment orders (CTOs) have been made each month - UK
The regulator also noted that there was a sharp rise in the doctors prescribing compulsory treatments for mental health problems. On average, 367 community treatment orders (CTOs) have been made each month. This is at least ten times the number anticipated when the legislation was introduced in 2008.
http://www.blogger.com/goog_194618019
Mental health patients 'locked up in hospitals without legal authority'
Health regulator says blanket measures introduced in the name of patient security may infringe human rights law
•Randeep Ramesh, social affairs editor
•The Guardian, Wednesday 27 October 2010
•Article history
Mental health patients are increasingly being locked up in hospitals without legal authority, a practice which may infringe human rights law, the health regulator said today.
The Care Quality Commission said the proportion of people in low secure beds has increased significantly since 2006. More than a quarter of psychiatric patients are now in held in low secure units (LSUs). Three years ago, the figure was less than a fifth.
Such changes in the pattern of care have rung alarm bells at the commission. It says patients were being subjected to a regime of close observation behind high fences and "airlocks", where patients sometimes faced "unsafe or abusive practices".
The regulator cited cases where the mentally ill were limited to "two to six sheets" of toilet paper and where nurses were unable to administer care because they were busy guarding patients.
One example saw a male nurse assigned "to preserve the dignity" of a highly disturbed female patient who was constantly attempting to remove her clothing. Other female patients in a different unit also complained that male nurses were involved "during night-time observation, bathing and toileting".
The commission said these were "serious concerns for the dignity and safety of vulnerable [people]". "Examples of poor practice being followed in the name of patient security included blanket measures that risked infringing human rights law, and disregard for privacy and dignity that was verging on unsafe or abusive practice," said the report.
There had also been an alarming trend of security measures that banned mobile phones or forbade patients from preparing their own meals. The commission said, in some circumstances, this could "amount to an unwarranted infringement of patients' ECHR article eight rights to a family and private life".
The commission recommends reviewing the national policy of standards in such units. Matt Kinton, the report's author, said there was a "real worry that the more mental health wards look like prisons, the less they function as hospitals where people will get better and be able to live independently".
Kinton said one of the driving forces of this trend towards security was that the private sector had built many new low-security wards. "It is the old adage that if you build a hospital, patients will fit it."
The regulator also noted that there was a sharp rise in the doctors prescribing compulsory treatments for mental health problems. On average, 367 community treatment orders (CTOs) have been made each month. This is at least ten times the number anticipated when the legislation was introduced in 2008.
Patients detained in hospital can be discharged under CTOs and supervised by a doctor who stipulates a strict prescription of medicines and can sometimes restrict patients movements. If a patient refuses, they can be returned to hospital. ends
http://www.blogger.com/goog_194618019
Mental health patients 'locked up in hospitals without legal authority'
Health regulator says blanket measures introduced in the name of patient security may infringe human rights law
•Randeep Ramesh, social affairs editor
•The Guardian, Wednesday 27 October 2010
•Article history
Mental health patients are increasingly being locked up in hospitals without legal authority, a practice which may infringe human rights law, the health regulator said today.
The Care Quality Commission said the proportion of people in low secure beds has increased significantly since 2006. More than a quarter of psychiatric patients are now in held in low secure units (LSUs). Three years ago, the figure was less than a fifth.
Such changes in the pattern of care have rung alarm bells at the commission. It says patients were being subjected to a regime of close observation behind high fences and "airlocks", where patients sometimes faced "unsafe or abusive practices".
The regulator cited cases where the mentally ill were limited to "two to six sheets" of toilet paper and where nurses were unable to administer care because they were busy guarding patients.
One example saw a male nurse assigned "to preserve the dignity" of a highly disturbed female patient who was constantly attempting to remove her clothing. Other female patients in a different unit also complained that male nurses were involved "during night-time observation, bathing and toileting".
The commission said these were "serious concerns for the dignity and safety of vulnerable [people]". "Examples of poor practice being followed in the name of patient security included blanket measures that risked infringing human rights law, and disregard for privacy and dignity that was verging on unsafe or abusive practice," said the report.
There had also been an alarming trend of security measures that banned mobile phones or forbade patients from preparing their own meals. The commission said, in some circumstances, this could "amount to an unwarranted infringement of patients' ECHR article eight rights to a family and private life".
The commission recommends reviewing the national policy of standards in such units. Matt Kinton, the report's author, said there was a "real worry that the more mental health wards look like prisons, the less they function as hospitals where people will get better and be able to live independently".
Kinton said one of the driving forces of this trend towards security was that the private sector had built many new low-security wards. "It is the old adage that if you build a hospital, patients will fit it."
The regulator also noted that there was a sharp rise in the doctors prescribing compulsory treatments for mental health problems. On average, 367 community treatment orders (CTOs) have been made each month. This is at least ten times the number anticipated when the legislation was introduced in 2008.
Patients detained in hospital can be discharged under CTOs and supervised by a doctor who stipulates a strict prescription of medicines and can sometimes restrict patients movements. If a patient refuses, they can be returned to hospital. ends
Wednesday, 27 October 2010
Evelyn Pringle - is this really professional journalism research?
Hi all,
I've decided to do a report on people who have committed crimes while on psych drugs or when they went off them.
Many people have emailed me with their stories and I
would like other people to do the same. I probably
won't get to it until after the Aug DC protest but will soon after that.
I'd appreciate any help you can give me in gathering this information.
Cheers,
Evie
http://groups.google.co.uk/group/parents-against-teenscreen/browse_thread/thread/e3525a2918071f91/318bd42b466489b5?hl=en&q=
I've decided to do a report on people who have committed crimes while on psych drugs or when they went off them.
Many people have emailed me with their stories and I
would like other people to do the same. I probably
won't get to it until after the Aug DC protest but will soon after that.
I'd appreciate any help you can give me in gathering this information.
Cheers,
Evie
http://groups.google.co.uk/group/parents-against-teenscreen/browse_thread/thread/e3525a2918071f91/318bd42b466489b5?hl=en&q=
Seroxat - Paxil "split pill" max payout $150 per person
Under the settlement, GSK denies liability and all of the claims in the lawsuit. If approved, the $28 million settlement will be split between consumers who paid for their Paxil and insurance companies seeking to be reimbursed for their expenditures. The amount each class member recovers will depend on how many defective pills they bought, with a maximum recovery of $150 per person. For a pill to be "defective" under the settlement, it must have split before it was removed from the container.
Paxil - Seroxat defect Puerto Rico was simply split pills - nobody harmed !
A proposed settlement has been reached in a case alleging a manufacturing defect in certain tablets of Paxil, the popular antidepressant drug manufactured by GlaxoSmithKline (GSK). If approved, the settlement will provide up to $28 million to claimants and their insurance companies.
The suit alleges that Paxil "controlled release" (CR) tablets made between April 1, 2002 and March 4, 2005, contained a manufacturing defect that caused them to split apart. In March 2005, armed marshals with the Food and Drug Administration (FDA) raided GSK plants in Puerto Rico and Tennessee after learning that some pills manufactured there had split apart. Two medications — Paxil and Avandamet, a diabetes medication — were being produced at the facilities. Although the investigation didn’t conclusively show that anyone had been harmed by the pills, the FDA said the burden was on the manufacturer to ensure that the medication was safe.
The FDA had originally discovered the problem at the Puerto Rico plant in February 2002, and the problem continued despite repeated warnings and inspections. GSK was unable to determine what was causing the problem, which concerned the FDA.
Paxil CR is a "controlled-release" version of the antidepressant, meaning that it releases medication slowly and evenly, in an attempt to deliver more consistent effects throughout the day. However, the CR version has not been compared to standard Paxil in lab tests, and some believe that any added benefits are negligible at best.
Split pills make it harder for patients to accurately estimate doses, and can render the "enteric coating," which controls the medication's time and rate of release, inactive. More importantly, the medically effective ingredients tend to remain in only one side of the pill after the split, making the other half comparable to a placebo. Taking a pill containing no medication could cause immediate withdrawal symptoms, as Paxil stays in the bloodstream for a shorter time than most other popular antidepressants.
Under the settlement, GSK denies liability and all of the claims in the lawsuit. If approved, the $28 million settlement will be split between consumers who paid for their Paxil and insurance companies seeking to be reimbursed for their expenditures. The amount each class member recovers will depend on how many defective pills they bought, with a maximum recovery of $150 per person. For a pill to be "defective" under the settlement, it must have split before it was removed from the container.
Potential class members who want to recover should fill out a claim form, available at the settlement Web site. Class members can also choose to exclude themselves from the settlement or object to its terms, but must do so by May 15 and July 1, respectively. A final approval hearing will be held on July 10, 2009. Plaintiffs are represented by the firms Strange & Carpenter and Salas & Co.
Read more: http://www.consumeraffairs.com/news04/2009/03/paxil_settlement02.html#ixzz13adNMbV7
The suit alleges that Paxil "controlled release" (CR) tablets made between April 1, 2002 and March 4, 2005, contained a manufacturing defect that caused them to split apart. In March 2005, armed marshals with the Food and Drug Administration (FDA) raided GSK plants in Puerto Rico and Tennessee after learning that some pills manufactured there had split apart. Two medications — Paxil and Avandamet, a diabetes medication — were being produced at the facilities. Although the investigation didn’t conclusively show that anyone had been harmed by the pills, the FDA said the burden was on the manufacturer to ensure that the medication was safe.
The FDA had originally discovered the problem at the Puerto Rico plant in February 2002, and the problem continued despite repeated warnings and inspections. GSK was unable to determine what was causing the problem, which concerned the FDA.
Paxil CR is a "controlled-release" version of the antidepressant, meaning that it releases medication slowly and evenly, in an attempt to deliver more consistent effects throughout the day. However, the CR version has not been compared to standard Paxil in lab tests, and some believe that any added benefits are negligible at best.
Split pills make it harder for patients to accurately estimate doses, and can render the "enteric coating," which controls the medication's time and rate of release, inactive. More importantly, the medically effective ingredients tend to remain in only one side of the pill after the split, making the other half comparable to a placebo. Taking a pill containing no medication could cause immediate withdrawal symptoms, as Paxil stays in the bloodstream for a shorter time than most other popular antidepressants.
Under the settlement, GSK denies liability and all of the claims in the lawsuit. If approved, the $28 million settlement will be split between consumers who paid for their Paxil and insurance companies seeking to be reimbursed for their expenditures. The amount each class member recovers will depend on how many defective pills they bought, with a maximum recovery of $150 per person. For a pill to be "defective" under the settlement, it must have split before it was removed from the container.
Potential class members who want to recover should fill out a claim form, available at the settlement Web site. Class members can also choose to exclude themselves from the settlement or object to its terms, but must do so by May 15 and July 1, respectively. A final approval hearing will be held on July 10, 2009. Plaintiffs are represented by the firms Strange & Carpenter and Salas & Co.
Read more: http://www.consumeraffairs.com/news04/2009/03/paxil_settlement02.html#ixzz13adNMbV7
Subscribe to:
Posts (Atom)





